Literature DB >> 2138366

The flow cytometric crossmatch and early renal transplant loss.

R J Mahoney1, K A Ault, S R Given, R J Adams, A C Breggia, P A Paris, G E Palomaki, S A Hitchcox, B W White, J Himmelfarb.   

Abstract

Data from this retrospective study indicate that a positive two-color T and/or B cell flow cytometric crossmatch (FCXM) is predictive of early renal allograft loss (less than 2 months) in cadaveric kidney donor recipients who had a negative crossmatch by the antihuman globulin complement-dependent cytotoxicity technique. Among 90 cadaveric kidney donor recipients (67 primary, 23 regrafts), 14 (8 primary, 6 regrafts) lost their renal allografts within 2 months, and 10 of the 14 were FCXM positive and HLA sensitized. The remaining 76 allografts survived beyond 2 months, 12 of which were FCXM-positive. Thus, the FCXM sensitivity rate for detecting early graft loss was 71%, and the specificity rate was 84%. Cadaveric graft-loss rates at 2 months were 33% for primary and 60% for FCXM-positive regrafts in contrast to 7% for primary and 0% for FCXM-negative regrafts. The difference in early graft loss between FCXM-positive and FCXM-negative recipients was statistically significant (P less than 0.0001). Subset analyses of FCXM-positive graft recipients indicate: (1) previous early graft loss contraindicates transplantation of an FXCM-positive regraft (P = 0.03); and (2) panel reactive antibody (PRA) less than or equal to 10% at crossmatch is not associated with early graft loss (P = 0.04). There was no significant difference in 1-year graft survival between primary and regrafts in either FCXM-negative recipients (85% vs. 77%, respectively) or FCXM-positive recipients (67% vs. 40%). All 12 of the FCXM-positive primary and regrafts that survived 2 months continued to function at 2 years. Stepwise logistic regression analysis of 5 independent predictor variables (FCXM status, gender, primary vs. regraft status, PRA level, and HLA mismatched antigens) indicated that the FCXM test was the best predictor of early graft loss. When FCXM results of the 90 cadaveric graft recipients were ranked in three groups, an FCXM channel shift of 29 or greater (third tertile) on a 1024 channel log scale was associated with a 7.0-fold (95% confidence interval 1.9-25.5) increased risk of early graft failure when compared to the first two tertiles. These data indicate that the FCXM offers an additional approach for identifying sensitized patients at risk of early renal allograft loss.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2138366     DOI: 10.1097/00007890-199003000-00011

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  10 in total

Review 1.  Moving Biomarkers toward Clinical Implementation in Kidney Transplantation.

Authors:  Madhav C Menon; Barbara Murphy; Peter S Heeger
Journal:  J Am Soc Nephrol       Date:  2017-01-06       Impact factor: 10.121

Review 2.  Kidney transplantation in highly sensitized patients: reappraisal of etiology, evaluation, and management protocols.

Authors:  R Indudhara; R B Khauli
Journal:  World J Urol       Date:  1996       Impact factor: 4.226

Review 3.  Utility of HLA Antibody Testing in Kidney Transplantation.

Authors:  Ana Konvalinka; Kathryn Tinckam
Journal:  J Am Soc Nephrol       Date:  2015-03-24       Impact factor: 10.121

Review 4.  Evolution of HLA antibody detection: technology emulating biology.

Authors:  Robert A Bray; Peter W Nickerson; Ronald H Kerman; Howard M Gebel
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

5.  The role of positive flow cytometry crossmatch in late renal allograft loss.

Authors:  Ralph J Graff; Huiling Xiao; Mark A Schnitzler; Patrick Ercole; Harvey Solomon; Tracy Pessin; Krista L Lentine
Journal:  Hum Immunol       Date:  2009-04-11       Impact factor: 2.850

6.  Crossmatch testing in kidney transplantation: patterns of practice and associations with rejection and graft survival.

Authors:  Paolo R Salvalaggio; Ralph J Graff; Brett Pinsky; Mark A Schnitzler; Steven K Takemoto; Thomas E Burroughs; Luiz S Santos; Krista L Lentine
Journal:  Saudi J Kidney Dis Transpl       Date:  2009-07

7.  Combining Sensitive Crossmatch Assays With Donor/Recipient Human Leukocyte Antigen Eplet Matching Predicts Living-Donor Kidney Transplant Outcome.

Authors:  Maria Meneghini; Edoardo Melilli; Jaume Martorell; Ignacio Revuelta; Elisabet Rigol-Monzó; Anna Manonelles; Nuria Montero; David Cucchiari; Fritz Diekmann; Josep M Cruzado; Salvador Gil-Vernet; Josep M Grinyó; Oriol Bestard
Journal:  Kidney Int Rep       Date:  2018-03-30

8.  Technical and clinical aspects of the histocompatibility crossmatch assay in solid organ transplantation

Authors:  Ana María Arrunátegui; Daniel S Ramón; Luz Marina Viola; Linda G Olsen; Andrés Jaramillo
Journal:  Biomedica       Date:  2022-06-01       Impact factor: 1.173

9.  Measuring alloreactive B cell responses in transplant recipients.

Authors:  Suheyla Hasgur; Anna Valujskikh
Journal:  Curr Transplant Rep       Date:  2019-01-24

Review 10.  Desensitization for solid organ and hematopoietic stem cell transplantation.

Authors:  Andrea A Zachary; Mary S Leffell
Journal:  Immunol Rev       Date:  2014-03       Impact factor: 12.988

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.